<DOC>
	<DOCNO>NCT00728507</DOCNO>
	<brief_summary>Although effective therapy tuberculosis available , TB continue cause significant problem worldwide , rate multi-drug resistant ( MDR ) TB case rise . A major obstacle control TB poor adherence lengthy ( usually 6 month ) complicate treatment regimen . Incomplete TB treatment lead serious consequence increase severity illness death , prolong infectiousness transmission community , development drug resistance . The development new treatment strategy strong drug could lead short simpler regimen . A TB treatment regimen allow treatment duration meaningfully decrease would important public health implication . This trial compare effect safety new oral regimen standard regimen first phase treatment pulmonary tuberculosis . The experimental regimen consist follow : - Two month isoniazid , rifapentine , pyrazinamide moxifloxacin ( HPZM ) administer daily . Pyridoxine ( vitamin B6 ) give dose isoniazid . The standard control intensive phase regimen consist follow : - Two month isoniazid , rifampin , pyrazinamide , ethambutol ( HRZE ) administer daily . Pyridoxine ( vitamin B6 ) give dose isoniazid . Following intensive phase therapy ( study phase ) , patient treat non-experimental continuation phase regimen . In mouse , combination Moxifloxacin Rifapentine cure animal significantly faster standard regimen study first step see potential also human .</brief_summary>
	<brief_title>Rifapentine Plus Moxifloxacin Treatment Pulmonary Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Presumptive diagnosis sputum smearpositive pulmonary TB . Age : ≥18 year Seven ( 7 ) few day multidrug therapy TB disease precede 6 month . Seven ( 7 ) few day fluoroquinolone therapy precede 3 month . Documentation HIV infection status . For HIV seropositive individual , CD4 T lymphocyte count great equal 200 cells/mm3 . Documentation study baseline laboratory parameter do , ≤ 14 day prior screen : AST le equal 2.5 time upper limit normal . Total bilirubin level le 2.5 time upper limit normal . Creatinine level le 2 time upper limit normal . Hemoglobin level least 8.0 g/dl . Platelet count least 75,000 mm3 . Potassium level least 3.5 . Negative pregnancy test ( woman childbearing potential ) . Karnofsky score least 60 ( require occasional assistance able care his/her need ) . Male nonpregnant , nonnursing female . Provision inform consent . CD4 count &lt; 200 cells/cu mm . Presence active AIDSrelated opportunistic infection ( TB ) active AIDSrelated malignancy . Known intolerance study drug . Concomitant disorder condition study drug contraindicate . These include severe hepatic damage , acute liver disease cause , acute uncontrolled gouty arthritis . Inability take oral medication . Central nervous system TB . Pulmonary silicosis . Current plan therapy , study phase ( intensive phase TB treatment ) , one follow drug : quinidine , procainamide , amiodarone , sotalol , disopyramide , terfenadine , cisapride , erythromycin , clarithromycin , phenothiazine , haloperidol , olanzapine , ziprasidone , tricyclic antidepressant , chronic corticosteroid administer either orally intravenously , chronic fluconazole , chronic itraconazole , chronic ketoconazole , oral intravenous tacrolimus , oral intravenous cyclosporine , HIV protease inhibitor , HIV nonnucleoside reverse transcriptase inhibitor . Concurrent severe and/or uncontrolled medical psychiatric condition , opinion investigator , could cause unacceptable safety risk compromise compliance protocol . Unable unwilling receive directly observe therapy and/or adhere followup ( e.g . due residence remote study site ) . Refusal consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Rifapentine</keyword>
</DOC>